ropinirole has been researched along with Sleep Wake Disorders in 14 studies
Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the effects of ropinirole prolonged-release (RPR) in comparison with ropinirole immediate-release (RIR) on sleep-related disorders in Parkinson disease (PD)." | 7.76 | Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. ( Busková, J; Dusek, P; Jech, R; Majerová, V; Roth, J; Růzicka, E; Sonka, K; Srp, A, 2010) |
| ") and restless legs syndrome treated with ropinirole and gabapentin, will be discussed." | 4.89 | Recent advances in sleep research. ( Anderer, P; Saletu, B; Saletu-Zyhlarz, GM, 2013) |
| "This study evaluated the effects of ropinirole prolonged-release (RPR) in comparison with ropinirole immediate-release (RIR) on sleep-related disorders in Parkinson disease (PD)." | 3.76 | Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. ( Busková, J; Dusek, P; Jech, R; Majerová, V; Roth, J; Růzicka, E; Sonka, K; Srp, A, 2010) |
| " Dosage of levodopa and oral DA (pramipexole ≤1." | 2.80 | Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study. ( Bauer, L; Chung, SJ; Ikeda, J; Jeon, BS; Kim, JM; Kim, JW; Singh, P; Thierfelder, S, 2015) |
| " The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole, ropinirole, and rasagiline." | 2.48 | Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. ( Tarrants, ML; Zagmutt, FJ, 2012) |
| "Two patients with Parkinson's disease received treatment with ropinirole and/or pramipexole, during which both experienced sleep attacks." | 1.31 | Non-ergot dopamine agonist-induced sleep attacks. ( Ryan, M; Slevin, JT; Wells, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amos, LB | 1 |
| Grekowicz, ML | 1 |
| Kuhn, EM | 1 |
| Olstad, JD | 1 |
| Collins, MM | 1 |
| Norins, NA | 1 |
| D'Andrea, LA | 1 |
| Saletu, B | 1 |
| Anderer, P | 1 |
| Saletu-Zyhlarz, GM | 1 |
| Kim, JM | 1 |
| Chung, SJ | 1 |
| Kim, JW | 1 |
| Jeon, BS | 1 |
| Singh, P | 1 |
| Thierfelder, S | 1 |
| Ikeda, J | 1 |
| Bauer, L | 1 |
| Rose, AR | 1 |
| Antic, NA | 1 |
| McEvoy, RD | 1 |
| Léger, D | 1 |
| Ogrizek, P | 1 |
| Dusek, P | 1 |
| Busková, J | 1 |
| Růzicka, E | 1 |
| Majerová, V | 1 |
| Srp, A | 1 |
| Jech, R | 1 |
| Roth, J | 1 |
| Sonka, K | 1 |
| Ray Chaudhuri, K | 1 |
| Martinez-Martin, P | 1 |
| Rolfe, KA | 1 |
| Cooper, J | 1 |
| Rockett, CB | 1 |
| Giorgi, L | 1 |
| Ondo, WG | 1 |
| Zagmutt, FJ | 1 |
| Tarrants, ML | 1 |
| Bonuccelli, U | 1 |
| Schapira, AH | 1 |
| Laustsen, G | 1 |
| Gilbert, M | 1 |
| Wimett, L | 1 |
| Spiegelhalder, K | 1 |
| Hornyak, M | 1 |
| Ryan, M | 1 |
| Slevin, JT | 1 |
| Wells, A | 1 |
| Moller, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance[NCT02882880] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B[NCT01723904] | Phase 3 | 90 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa[NCT00381472] | Phase 3 | 393 participants | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Absolute time spent off is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent off decreased from Baseline and therefore indicates an improvement from Baseline.~Only subjects with time spent off at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure." (NCT01723904)
Timeframe: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | hours/day (Mean) |
|---|---|
| Rotigotine | -2.1 |
"UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible).~UPDRS Part II total score (average of on and off state) is the average of UPDRS Part II total score (on state) and Part II total score (off state).~A negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline." (NCT01723904)
Timeframe: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | units on a scale (Mean) |
|---|---|
| Rotigotine | -1.5 |
"The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108.~A negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline." (NCT01723904)
Timeframe: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | units on a scale (Mean) |
|---|---|
| Rotigotine | -5.3 |
"Absolute time spent on without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent on without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline." (NCT01723904)
Timeframe: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | hours/day (Mean) |
|---|---|
| Rotigotine | 1.9 |
"The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions.~A negative value in Change from Baseline to Week 8 indicates an improvement from Baseline." (NCT01723904)
Timeframe: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | units on a scale (Mean) |
|---|---|
| Rotigotine | -3.2 |
"The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality.~A negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline." (NCT01723904)
Timeframe: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | units on a scale (Mean) |
|---|---|
| Rotigotine | -0.7 |
"The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable~= No side effects~= Side effects do not significantly interfere with subject's functioning~= Side effects significantly interfere with the subject's functioning~= Side effects outweigh therapeutic efficacy." (NCT01723904)
Timeframe: Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| CGI Item 4 score of 1 | CGI Item 4 score of 2 | CGI Item 4 score of 3 | CGI Item 4 score of 4 | CGI Item 4 score of 3 or 4 | |
| Rotigotine | 61 | 22 | 3 | 3 | 6 |
6 reviews available for ropinirole and Sleep Wake Disorders
| Article | Year |
|---|---|
Recent advances in sleep research.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Amines; Antiparkinson Agents; Biomedical Research; | 2013 |
[Sleep disorders in adults].
Topics: Adult; Benzodiazepines; Diagnosis, Differential; Disorders of Excessive Somnolence; Dopamine Agonist | 2008 |
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
Topics: Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Cross-Sectional Studies; Databases, Bibli | 2012 |
Comparing dopamine agonists in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Randomized C | 2003 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; | 2005 |
Restless legs syndrome in older adults.
Topics: Aged, 80 and over; Benzothiazoles; Cabergoline; Circadian Rhythm; Cognition Disorders; Comorbidity; | 2008 |
2 trials available for ropinirole and Sleep Wake Disorders
| Article | Year |
|---|---|
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Benzothiazoles; Dopamine Agonists; Fema | 2015 |
Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Indole | 2012 |
6 other studies available for ropinirole and Sleep Wake Disorders
| Article | Year |
|---|---|
Treatment of pediatric restless legs syndrome.
Topics: Adolescent; Amines; Analgesics; Anticonvulsants; Antioxidants; Benzothiazoles; Child; Child, Prescho | 2014 |
Restless leg syndrome, dopamine agonists and sleep attacks.
Topics: Aged, 80 and over; Dopamine Agonists; Female; Humans; Indoles; Restless Legs Syndrome; Sleep Wake Di | 2008 |
Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Rel | 2010 |
A look back at the most influential drug approvals of 2005.
Topics: Amyloid; Analgesics; Anticonvulsants; Antiparkinson Agents; Diabetes Mellitus, Type 2; Diphtheria-Te | 2006 |
Non-ergot dopamine agonist-induced sleep attacks.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disea | 2000 |
Antiparkinsonian drugs and "sleep attacks".
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antiparkinson Agents; Automobile Driving; Benzothiazo | 2001 |